In June 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) will convene a meeting of the Cellular, Tissue, and Gene Therapies Advisory ...
On March 27, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has granted an Advisory Committee (AdCom) meeting to discuss the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results